Daily Stock Analysis, ACER, Opexa Therapeutics Inc, priceseries

Opexa Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
3.30
Close
3.41
High
3.45
Low
3.25
Previous Close
3.23
Daily Price Gain
0.18
YTD High
28.25
YTD High Date
Apr 11, 2019
YTD Low
1.87
YTD Low Date
Aug 16, 2019
YTD Price Change
-18.04
YTD Gain
-84.10%
52 Week High
32.75
52 Week High Date
Sep 14, 2018
52 Week Low
1.87
52 Week Low Date
Aug 16, 2019
52 Week Price Change
-26.70
52 Week Gain
-88.67%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 12. 2017
11.98
Jan 13. 2017
13.12
1 Trading Days
9.50%
Link
LONG
Feb 14. 2017
11.56
Feb 15. 2017
12.34
1 Trading Days
6.76%
Link
LONG
Jul 3. 2017
12.19
Jul 5. 2017
13.65
1 Trading Days
11.97%
Link
LONG
Sep 6. 2017
9.27
Sep 20. 2017
10.03
10 Trading Days
8.24%
Link
LONG
Sep 25. 2017
11.00
Oct 18. 2017
17.25
17 Trading Days
56.82%
Link
LONG
Dec 29. 2017
13.85
Feb 2. 2018
18.72
23 Trading Days
35.14%
Link
LONG
Aug 3. 2018
21.10
Aug 16. 2018
26.27
9 Trading Days
24.52%
Link
LONG
Aug 17. 2018
28.94
Sep 6. 2018
31.32
13 Trading Days
8.24%
Link
LONG
Dec 31. 2018
20.12
Jan 24. 2019
24.12
16 Trading Days
19.89%
Link
Company Information
Stock Symbol
ACER
Exchange
NasdaqCM
Company URL
http://www.opexatherapeutics.com
Company Phone
(281) 272-9331
CEO
Neil K. Warma
Headquarters
Texas
Business Address
2635 TECHNOLOGY FOREST BLVD., THE WOODLANDS, TX 77381
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001069308
About

Opexa Therapeutics, Inc. engages as a biopharmaceutical company, which develops personalized immunotherapy with the potential to treat major illnesses including multiple sclerosis and other autoimmune diseases. Its product candidates include Tcelna and OPX-212. The company was founded in March 1991 and is headquartered in The Woodlands, TX.

Description

Opexa Therapeutics, Inc., a biopharmaceutical company, develops personalized immunotherapy to treat multiple sclerosis (MS) and other autoimmune diseases based on its proprietary T-cell technology. The company's lead product candidate is Tcelna, a novel T-cell immunotherapy, which is in Phase IIb clinical development for the treatment of patients with secondary progressive MS. It is also developing OPX-212 as an autologous T-cell immunotherapy that is in preclinical development to treat neuromyelitis optica. The company was formerly known as PharmaFrontiers Corp. and changed its name to Opexa Therapeutics, Inc. in June 2006. Opexa Therapeutics, Inc. was founded in 2003 and is based in The Woodlands, Texas.